

## For Health Professionals Who Care for Cancer Patients

### Inside This Issue:

#### Editor's Choice

Expanded Eligibility for Oncotype® DX Breast Cancer Assay

#### Drug Update

Capecitabine Weekly Nursing Assessments

#### Provincial Systemic Therapy Program

**New** Therapeutic Automatic Substitution Policy | **Updated** Pharmacy Practice Standards for Hazardous Drugs Manual | High Alert Medications Policy | Systemic Therapy Treatment Delivery Process Policy

#### Drug Shortages

**New** Paclitaxel NAB | **Resolved** Testosterone Enanthate

#### Cancer Drug Manual®

**Revised** Bevacizumab, Dacarbazine, Fluorouracil, Interferon Alfa-2b, Mitomycin, Pembrolizumab | CDM Editorial Board Changes

#### Revised Protocols, PPPOs & Patient Handouts

**BR** BRAJCAP, BRAVCAP, BRAVLCAP, BRAVTCAP | **CN** CNAJZRT | **GI** GIA, GIAJCAP, GIAJCAPOX, GIAJFFOX, GIAVCAP, GIAVCAPB, GIAVCETIR, GIAVCRT, GIAVFL, GIAVPANI, GIAVPG, GIAVTZCAP, GIBAJCAP, GICAPIRI, GICAPOX, GICART, GICIRB, GICOXB, GICPART, GIEFFOXRT, GIFFIRB, UGIFFIRPAN, GIFFOXB, UGIFFOXPAN, GIFIRINOX, GIFOLFIRI, GIFOLFOX, GIFUART, GIFUPART, GIGAJCOX, GIGAJCPRT, GIGAVCC, GIGAVCCT, GIGAVCOX, GIGAVCOXT, GIGAVFFOX, GIGAVFFOXT, GIGECC, GIGFOLFIRI, GIPAJFIROX, GIPAJGAP, GIPAJGEM, GIPAVCAP, GIPAVFFIRI, GIPAVFFOX, GIPE, GIPGEMABR, GIRAJCOX, GIRAJFFOX, GIRCAP, GIRCRT, GIRINFRT | **HN** HNAVCP, UHNAVPCPMB, HNAVCP | **LK** ULKMSA | **MY** UMYBLDF, UMYCARLD, UMYDARLD, UMYLDF, UMYLDREL, UMYLENMTN, UMYPOMDEX | **SC** SCHYPCAL, SCNAUSEA

#### Resources and Contact Information

### Editor's Choice

#### Expanded Eligibility for Oncotype® DX Breast Cancer Assay

##### Breast

BC Cancer is expanding the eligibility for the **Oncotype DX® Breast Cancer Assay** effective 01 October 2021. Eligibility now includes **node-positive disease (micro-metastases or macro-metastases in 1-3 axillary lymph nodes)** in hormone receptor-positive, HER2-negative **postmenopausal** breast cancer patients (irrespective of the grade and size of the primary tumour). All other eligibility criteria for Oncotype DX® remain unchanged.

The Oncotype DX® eligibility expansion is supported by emerging prognostic data suggesting no discernable benefit to adjuvant chemotherapy in women with an Oncotype DX® recurrence score of 1-25 and node-positive (1-3 axillary lymph nodes), hormone receptor-positive, HER2-negative postmenopausal breast cancer. As this patient population is prevalent, results from this assay can help to avoid unnecessary adjuvant chemotherapy and therefore chemotherapy-associated morbidity and mortality in patients. Other benefits include reductions in drugs costs and in resource utilization.

## Drug Update

### Capecitabine Weekly Nursing Assessments

Patients receiving capecitabine-containing treatment regimens within the Breast and Head and Neck tumour sites will have optional, weekly assessments with nurses by phone effective 01 October 2021.

This initiative is in response to a pilot study at BC Cancer – Vancouver, where nurses provided weekly assessments by phone for patients starting capecitabine treatment. Both patients and practitioners found the assessments beneficial.

Moving forward, the Breast and Head and Neck Provincial Pre-Printed Orders (PPPOs) for capecitabine-containing treatment will include a **check box** for this optional nursing assessment:

**weekly nursing assessment**

This change aligns the Breast and Head and Neck PPPOs with the Gastrointestinal PPPOs that already have this optional assessment in place through CAIS and Cerner.

The weekly nursing assessment should be considered for a patient's first two capecitabine cycles, when the dose is increased, or when clinically indicated.

## Provincial Systemic Therapy Program

All policies and procedures are on the Shared Health Organizations Portal (SHOP) [BC Cancer page](#).

### New: Therapeutic Automatic Substitution Policy

**Policy III-210: Therapeutic Automatic Substitution** has been approved effective 01 October 2021.

The therapeutic interchange of medications is necessary to maintain a safe and efficient hospital formulary, particularly in response to medication shortages. This may require the development of pre-printed orders (PPOs) to facilitate the automatic substitution of medications without the need to contact the prescriber.

The purpose of this policy is to provide a foundation for safe, consistent and efficient communication of therapeutic interchanges in compliance with Accreditation Canada Medication Management Standards.

## Provincial Systemic Therapy Program

### Updated: BC Cancer Pharmacy Practice Standards for Hazardous Drugs Manual

The **BC Cancer Pharmacy Practice Standards for Hazardous Drugs Manual**, known more commonly as the **Safe Handling Standards Manual**, has been updated in response to changes outlined by the National Association of Pharmacy Regulatory Authorities (NAPRA). The updated content is available in the [Safe Handling Standards Manual](#) section of the BC Cancer website.

Key updates include:

- A new section on *Decontaminating, Cleaning, Deactivating, Disinfecting and Sporicidals*
- Clarification of requirements for rooms in the controlled area
- Specifications of the hazardous drug storage room
- Personal Protective Equipment updates including use of an elastomeric, half-face mask respirator with appropriate filter cartridges (which replaces the N95 respirator) when cleaning and decontaminating the Biological Safety Cabinet and when cleaning a hazardous drug spill

Questions about these updates may be directed to the BC Cancer Pharmacy Oncology Certification Program team at [rxchemocert@bccancer.bc.ca](mailto:rxchemocert@bccancer.bc.ca).

### Updated: High Alert Medications Policy

The **BC Cancer Provincial High Alert Medications Policy** has been updated effective 01 October 2021:

Section	Update
Appendix A	Diacetylmorphine added to the High Alert Medications List
Appendix B	Scope of BC Cancer High Alert Oncology Medication Evaluation clarified
Appendix C	BC Cancer High Alert Medication approval process added

### Updated: Systemic Therapy Treatment Delivery Process Policy

**Policy III-10: Systemic Therapy Treatment Delivery Process** has been updated effective 01 October 2021:

Section	Update
2.3 Policy Statement #3 <b>Prescriber process</b> ➤ Pregnancy assessment	Language and link to Provincial Pregnancy Assessment and Education Policy

## Drug Shortages

The following are updates of drug supply shortages in BC. Full details about new, updated or resolved drug shortages, including recommended treatment alternatives, are found in the *Briefing Notes* and email communications previously circulated to BC Cancer and the Community Oncology Network (CON).

### New

#### Paclitaxel NAB (ABRAXANE)

(Adapted from BC Cancer Briefing Note 24 September 2021)

The manufacturer of paclitaxel NAB (ABRAXANE) has advised that there is a possible shortage due to a global manufacturing issue. Based on typical usage, there is an estimated 2-3 week supply available at regional BC Cancer centre pharmacies.

Paclitaxel NAB is used in the treatment of pancreatic cancer, breast cancer and gynecologic cancers. As the recommended first-line treatment for pancreatic cancer, supply should be prioritized for these patients. Supply should also be prioritized for patients who have had a previous severe hypersensitivity reaction or anaphylaxis to paclitaxel that is not manageable despite premedications. Scheduling patients receiving paclitaxel NAB on the same day may minimize drug wastage. Where possible, new patients should be started on alternatives as outlined in the following table. Potential treatment alternatives should be discussed with the appropriate Tumour Group.

PROTOCOL	INDICATION	TREATMENT ALTERNATIVES
<b>Breast</b>		
BRAVABR	Palliative therapy for metastatic breast cancer	An alternate protocol such as: <ul style="list-style-type: none"><li>➤ docetaxel (i.e., BRAVDOC, BRAVDOC7)</li><li>➤ paclitaxel (i.e., BRAVTAX, BRAVTW)</li></ul>
<b>Gastrointestinal</b>		
GIPGEMABR	First-line treatment of locally advanced and metastatic pancreatic cancer	<ul style="list-style-type: none"><li>➤ Prioritize GIPGEMABR for first-line treatment of pancreatic cancer</li><li>➤ GIFIRINOX may be an option in some patients</li></ul>
<b>Gynecologic</b>		
GOCABR GOCABRBEV	Alternative treatment of gynecologic malignancies	<ul style="list-style-type: none"><li>➤ Prioritize GOCABR / GOCABRBEV for patients with severe hypersensitivity reaction/anaphylaxis to paclitaxel</li><li>➤ GOOVFLDC may be an option in some patients</li></ul>

### Resolved

#### Testosterone Enanthate Injection

(Adapted from BC Cancer e-mail communication 24 September 2021)

The shortage has now been resolved.

All documents are available in the [Cancer Drug Manual<sup>®</sup>](#) on the BC Cancer website.

### Revised Documents

#### **Fluorouracil Monograph**

*Dosage Guidelines:* expanded dosing to include more information on ocular (topical) administration

#### **Mitomycin Monograph**

*Parenteral Administration table:* revised “intraocular” administration to “ocular (topical)”

*Dosage Guidelines:* revised “intraocular” administration to “ocular (topical)”

#### **Pembrolizumab Monograph**

*Uses:* added new Health Canada-approved indications (bladder cancer, head and neck cancer)

#### **Chemotherapy Preparation and Stability Chart**

**Bevacizumab (ZIRABEV):** added extended stability to Product Stability column

**Dacarbazine:** revised suggested bag volume to reflect current protocols

**Interferon Alfa-2b:** deleted formulations that have no remaining inventory at BC Cancer (drug has been discontinued globally by manufacturer)

### CDM Editorial Board Changes

The Cancer Drug Manual<sup>®</sup> Editorial Review Board would like to bid farewell to **Dr. Dave Fenton** (medical oncologist, BC Cancer – Victoria). Thank you, Dave, for your many years of contributions to the Cancer Drug Manual<sup>®</sup> board. We wish you all the best in your future endeavours.

## Highlights of New & Revised Protocols, PPPOs and Patient Handouts

**BC Cancer Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts** are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program (CAP) approval are prefixed with the letter **U**.

### REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>BR   Breast</b>				
<b>BRAJCAP</b>	Therapy of Adjuvant Breast Cancer using Capecitabine	<i>Tests updated; auxiliary information removed</i>	<i>Weekly nursing assessment added</i>	-----
<b>BRAVCAP</b>	Therapy of Metastatic Breast Cancer using Capecitabine	<i>Tests updated; auxiliary information removed</i>	<i>Weekly nursing assessment added</i>	-----
<b>BRAVLCAP</b>	Therapy for Metastatic Breast Cancer using Capecitabine and Lapatinib	<i>Tests updated; auxiliary information removed</i>	<i>Weekly nursing assessment added</i>	-----
<b>BRAVTCAP</b>	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab and Capecitabine	<i>Tests updated; auxiliary information removed</i>	<i>Tests revised; weekly nursing assessment added</i>	-----
<b>CN   Neuro-Oncology</b>				
<b>CNAJZRT</b>	Concomitant (Dual Modality) and Adjuvant Temozolomide for Newly Diagnosed Malignant Gliomas with Radiation	<i>Eligibility clarified</i>	-----	-----
<b>GI   Gastrointestinal</b>				
<b>GIA</b>	Palliative Therapy for Hepatoma using Doxorubicin	<i>Eligibility, Cautions, GI ST physician and contact information updated</i>	-----	-----
<b>GIAJCAP</b>	Adjuvant Therapy of Colon Cancer using Capecitabine	<i>Tests, Treatment and GI ST physician and contact information updated; auxiliary information removed</i>	<i>Chemotherapy updated</i>	-----
<b>GIAJCAPOX</b>	Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer using Oxaliplatin and Capecitabine	<i>Tests and GI ST physician and contact information updated</i>	-----	-----
<b>GIAJFFOX</b>	Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer using Oxaliplatin, Fluorouracil and Leucovorin	<i>Eligibility and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	-----	-----
<b>GIAVCAP</b>	Palliative Therapy of Advanced Colorectal Cancer using Capecitabine	<i>Tests and GI ST physician and contact information updated; auxiliary information removed</i>	<i>Chemotherapy updated</i>	-----

## REVISED Protocols, PPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPO	Handout
<b>GI   Gastrointestinal</b> <i>(continued)</i>				
<b>GIAVCAPB</b>	Palliative Therapy of Metastatic Colorectal Cancer using Capecitabine and Bevacizumab	<i>Tests, Monitoring and GI ST physician and contact information updated</i>	----	----
<b>GIAVCETIR</b>	BC Cancer Protocol Summary <a href="#">for</a> Third-Line Treatment of Metastatic Colorectal Cancer using Cetuximab in Combination with Irinotecan	<i>Protocol title, Eligibility and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	----	----
<b>GIAVCRT</b>	Combined Modality Therapy for Metastatic Rectal Carcinoma using Capecitabine and Radiation Therapy	<i>Tests and GI ST physician and contact information updated; auxiliary information removed</i>	----	----
<b>GIAVFL</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Fluorouracil Injection and Infusion and Leucovorin Infusion	<i>Eligibility and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	----	----
<b>GIAVPANI</b>	Palliative Third-Line Treatment of Metastatic Colorectal Cancer using Panitumumab	<i>Eligibility and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	----	----
<b>GIAVPG</b>	First-Line Palliative Chemotherapy for Advanced Gallbladder Cancer and Cholangiocarcinoma using Gemcitabine and Cisplatin	<i>Eligibility and GI ST physician and contact information updated; Cautions section added</i>	----	----
<b>GIAVTZCAP</b>	Palliative Therapy of Metastatic Neuroendocrine Cancer using Temozolomide and Capecitabine	<i>Eligibility, Tests, Monitoring and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section; auxiliary information removed</i>	----	----
<b>GIBAJCAP</b>	Adjuvant Therapy of Biliary Cancer using Capecitabine	<i>Eligibility, Cautions, Tests and GI ST physician and contact information updated; auxiliary information removed</i>	----	----
<b>GICAPIRI</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Irinotecan and Capecitabine in Patients Unsuitable for GIFOLFIRI	<i>Eligibility, Tests, Monitoring and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	----	----
<b>GICAPOX</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin and Capecitabine	<i>Tests and GI ST physician and contact information updated</i>	----	----

## REVISED Protocols, PPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPO	Handout
<b>GI   Gastrointestinal</b> <i>(continued)</i>				
<b>GICART</b>	Curative Combined Modality Therapy for Carcinoma of the Anal Canal using Mitomycin, Capecitabine and Radiation Therapy	<i>Eligibility, Tests and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section; auxiliary information removed</i>	-----	-----
<b>GICIRB</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Irinotecan, Bevacizumab and Capecitabine	<i>Eligibility, Tests, Monitoring and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	-----	-----
<b>GICOXB</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Bevacizumab and Capecitabine	<i>Tests and GI ST physician and contact information updated</i>	-----	-----
<b>GICPART</b>	Curative Combined Modality Therapy for Carcinoma of the Anal Canal using Cisplatin, Capecitabine and Radiation Therapy	<i>Eligibility, Tests and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section; auxiliary information removed</i>	-----	-----
<b>GIEFFOXRT</b>	Combined Modality Therapy for Locally Advanced Esophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Radiation Therapy	<i>Eligibility and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	-----	-----
<b>GIFFIRB</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Irinotecan, Fluorouracil, Leucovorin and Bevacizumab	<i>Eligibility and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	-----	-----
<b>UGIFFIRPAN</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Irinotecan, Fluorouracil, Leucovorin and Panitumumab	<i>Eligibility and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	-----	-----
<b>GIFFOXB</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Bevacizumab	<i>Eligibility and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	-----	-----
<b>UGIFFOXPAN</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Panitumumab	<i>Eligibility and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	-----	-----
<b>GIFIRINOX</b>	Palliative Combination Chemotherapy for Advanced Pancreatic Adenocarcinoma using Irinotecan, Oxaliplatin, Fluorouracil and Leucovorin	<i>Eligibility, Cautions and GI ST physician and contact information updated</i>	-----	-----



## REVISED Protocols, PPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPO	Handout
<b>GI   Gastrointestinal</b> <i>(continued)</i>				
<b>GIFOLFIRI</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Irinotecan, Fluorouracil and Leucovorin	<i>Eligibility and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	----	----
<b>GIFOLFOX</b>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, Fluorouracil and Leucovorin	<i>Eligibility and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	----	----
<b>GIFUART</b>	Curative Combined Modality Therapy for Carcinoma of the Anal Canal using Mitomycin, Infusional Fluorouracil and Radiation Therapy	<i>Eligibility and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	----	----
<b>GIFUPART</b>	Curative Combined Modality Therapy for Carcinoma of the Anal Canal using Cisplatin, Infusional Fluorouracil and Radiation Therapy	<i>Eligibility and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	----	----
<b>GIGAJCOX</b>	Adjuvant Chemotherapy in Gastric Cancer Patients with D2 Resection (Node-Negative) or Ineligible for Adjuvant Chemoradiation using Oxaliplatin and Capecitabine	<i>Tests, Monitoring and GI ST physician and contact information updated</i>	----	----
<b>GIGAJCPRT</b>	Adjuvant Chemotherapy of Gastric Cancer Patients with Completely Resected Gastric Cancer using Cisplatin and Capecitabine and Radiation Therapy	<i>Tests and GI ST physician and contact information updated; auxiliary information removed</i>	----	----
<b>GIGAVCC</b>	Palliative Therapy of Metastatic or Locally Advanced Anal Squamous Cell Carcinoma using Cisplatin and Capecitabine	<i>Tests and GI ST physician and contact information updated; auxiliary information removed</i>	----	----
<b>GIGAVCCT</b>	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Cisplatin, Capecitabine and Trastuzumab	<i>Tests and GI ST physician and contact information updated; auxiliary information removed</i>	----	----
<b>GIGAVCOX</b>	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Capecitabine and Oxaliplatin	<i>Tests and GI ST physician and contact information updated</i>	----	----
<b>GIGAVCOXT</b>	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Capecitabine, Oxaliplatin and Trastuzumab	<i>Tests and GI ST physician and contact information updated</i>	----	----
<b>GIGAVFFOX</b>	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Oxaliplatin, Fluorouracil and Leucovorin	<i>Eligibility and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	----	----

## REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>GI   Gastrointestinal</b> <i>(continued)</i>				
<b>GIGAVFFOXT</b>	Palliative Treatment of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma using Oxaliplatin, Fluorouracil, Leucovorin and Trastuzumab	<i>Eligibility and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	----	----
<b>GIGECC</b>	Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower ½ Esophagus using Epirubicin, Cisplatin and Capecitabine	<i>Tests and GI ST physician and contact information updated; auxiliary information removed</i>	----	-----
<b>GIGFOLFIRI</b>	Second-Line Palliative Combination Chemotherapy for Metastatic Gastric or Esophageal Adenocarcinoma using Irinotecan, Fluorouracil and Leucovorin	<i>Eligibility and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	----	----
<b>GIPAJFIROX</b>	Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma using Irinotecan, Oxaliplatin, Fluorouracil and Leucovorin	<i>Eligibility, Cautions and GI ST physician and contact information updated</i>	----	----
<b>GIPAJGCAP</b>	Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma using Capecitabine and Gemcitabine	<i>Eligibility, Tests and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section; auxiliary information removed</i>	----	----
<b>GIPAJGEM</b>	Adjuvant Chemotherapy for Pancreatic Adenocarcinoma using Gemcitabine	<i>Eligibility and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	----	----
<b>GIPAVCAP</b>	Second-Line Treatment of Metastatic or Unresectable Pancreatic Adenocarcinoma using Capecitabine	<i>Tests and GI ST physician and contact information updated; auxiliary information removed</i>	----	----
<b>GIPAVFFIRI</b>	Second-Line Treatment for Metastatic Pancreatic Cancer using Irinotecan, Fluorouracil and Leucovorin	<i>Eligibility and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	----	----
<b>GIPAVFFOX</b>	Palliative Combination Chemotherapy for Metastatic Pancreatic Cancer using Oxaliplatin, Fluorouracil and Leucovorin	<i>Eligibility and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	----	----
<b>GIPE</b>	Palliative Therapy of Neuroendocrine Tumours using Cisplatin and Etoposide	<i>Eligibility and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	----	----

## REVISED Protocols, PPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPO	Handout
<b>GI   Gastrointestinal</b> <i>(continued)</i>				
<b>GIPGEMABR</b>	First-Line Treatment of Locally Advanced and Metastatic Pancreatic Cancer with Paclitaxel NAB (ABRAXANE) and Gemcitabine	<i>Eligibility, Cautions and GI ST physician and contact information updated</i>	----	----
<b>GIRAJCOX</b>	Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal Cancer using Oxaliplatin and Capecitabine	<i>Tests and GI ST physician and contact information updated</i>	----	----
<b>GIRAJFFOX</b>	Adjuvant or Neoadjuvant Combination Chemotherapy for Stage III Rectal Cancer using Oxaliplatin, Fluorouracil and Leucovorin	<i>Eligibility and GI ST physician and contact information updated; cautions moved from Eligibility to new Cautions section</i>	----	----
<b>GIRCAP</b>	Adjuvant Therapy for Stage II and III Rectal Cancer Previously Treated with Preoperative Radiation Therapy using Capecitabine	<i>Tests, Treatment and GI ST physician and contact information updated; auxiliary information removed</i>	<i>Chemotherapy updated</i>	----
<b>GIRCRT</b>	Combined Modality Adjuvant Therapy for High-Risk Rectal Carcinoma using Capecitabine and Radiation Therapy	<i>Tests and GI ST physician and contact information updated; auxiliary information removed</i>	----	----
<b>GIRINFRT</b>	Combined Modality Adjuvant Therapy for High-Risk Rectal Carcinoma using Capecitabine, Infusional Fluorouracil and Radiation Therapy	<i>Tests and GI ST physician and contact information updated; auxiliary information removed</i>	----	----
<b>HN   Head and Neck</b>				
<b>HNAVCAP</b>	Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck with Capecitabine	<i>Tests updated; auxiliary information removed</i>	<i>Weekly nursing assessment added</i>	----
<b>UHNAVPCPMB</b>	First-Line Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck with Paclitaxel, Carboplatin and Pembrolizumab	----	<i>Paclitaxel dose revised to match protocol (175 mg/m<sup>2</sup>)</i>	----
<b>HNAVCAP</b>	Treatment of Recurrent or Metastatic Nasopharyngeal Cancer with Capecitabine	<i>Tests updated; auxiliary information removed</i>	<i>Weekly nursing assessment added</i>	----
<b>LK   Leukemia</b>				
<b>ULKMDSA</b>	Therapy of Myelodysplastic Syndrome and Acute Myeloid Leukemia using Azacitidine	<i>Eligibility updated</i>	----	----
<b>MY   Myeloma</b>				
<b>UMYBLDF</b>	Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Bortezomib, Lenalidomide and Dexamethasone	<i>Pregnancy test clarified</i>	<i>Test revised</i>	----

## REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>MY   Myeloma</b> <i>(continued)</i>				
<b>UMYCARLD</b>	Therapy of Multiple Myeloma using Carfilzomib, Lenalidomide with Dexamethasone	<i>Pregnancy test clarified</i>	<i>Test revised</i>	----
<b>UMYDARLD</b>	Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Lenalidomide and Dexamethasone	<i>Pregnancy test clarified</i>	<i>Test revised Cycle 1 and Cycle 2+ PPPOs</i>	----
<b>UMYLDF</b>	Treatment of Previously Untreated Multiple Myeloma and Not Eligible for Stem Cell Transplant using Lenalidomide with Low-Dose Dexamethasone	<i>Pregnancy test clarified</i>	<i>Test revised</i>	----
<b>UMYLDREL</b>	Therapy of Relapsed Multiple Myeloma using Lenalidomide with Dexamethasone	<i>Pregnancy test clarified</i>	<i>Test revised</i>	----
<b>UMYLENMTN</b>	Maintenance Therapy of Multiple Myeloma using Lenalidomide	<i>Pregnancy test clarified</i>	<i>Test revised</i>	----
<b>UMYPOMDEX</b>	Therapy of Multiple Myeloma using Pomalidomide with Dexamethasone	<i>Pregnancy test clarified</i>	<i>Test revised</i>	----
<b>SC   Supportive Care</b>				
<b>SCHYPCAL</b>	Guidelines for the Diagnosis and Management of Malignancy-Related Hypercalcemia	<i>Deleted</i>	----	----
<b>SCNAUSEA</b>	Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in Adults	<i>Use of olanzapine clarified; Pharmacare coverage comment updated; Physician Contact updated</i>	----	----

## Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: <a href="http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update">www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update</a>		
Systemic Therapy Update Editor	604-877-6000 x 672649	<a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>
Oncology Drug Information	604-877-6275	<a href="mailto:druginfo@bccancer.bc.ca">druginfo@bccancer.bc.ca</a>
Cancer Drug Manual Editor	250-519-5500 x 693742	<a href="mailto:nbadry@bccancer.bc.ca">nbadry@bccancer.bc.ca</a>
Pharmacy Oncology Certification	250-712-3900 x 686820	<a href="mailto:rxchemocert@bccancer.bc.ca">rxchemocert@bccancer.bc.ca</a>
Nurse Educators	604-877-6000 x 672638	<a href="mailto:nursinged@bccancer.bc.ca">nursinged@bccancer.bc.ca</a>
CAP – Compassionate Access Program	604-877-6277	<a href="mailto:cap_bcca@bccancer.bc.ca">cap_bcca@bccancer.bc.ca</a> fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	<a href="mailto:oscar@bccancer.bc.ca">oscar@bccancer.bc.ca</a> fax 604-708-2051
Manufacturer Patient Assistance Programs: <a href="http://www.bccancer.bc.ca/mpap">http://www.bccancer.bc.ca/mpap</a>		
Library/Cancer Information	604-675-8003	<a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a> toll free 888-675-8001 x 8003
Library Document Delivery	604-675-8002	<a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Pharmacy Professional Practice	604-877-6000 x 672247	<a href="mailto:mclin@bccancer.bc.ca">mclin@bccancer.bc.ca</a>
Professional Practice, Nursing	604-877-6000 x 672623	<a href="mailto:BCcancerPPNAdmin@ehcnet.phsa.ca">BCcancerPPNAdmin@ehcnet.phsa.ca</a>
Provincial Systemic Therapy Program	604-877-6000 x 672247	<a href="mailto:mclin@bccancer.bc.ca">mclin@bccancer.bc.ca</a>
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: <a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>		

## Editorial Review Board

Anne Dar Santos, BScPharm, PharmD (Editor)  
 Rose-Marie Reddy, BScPharm, PharmD (Interim Assistant Editor)  
 Mario de Lemos, PharmD, MSc(Oncol)

Jeevan Dosanjh, RN, BScN  
 Alina Gerrie, MD, MPH, FRCPC  
 Alison Pow, BScPharm